

Clinical trials of immune checkpoint inhibition for advanced urothelial carcinoma in all type of patients

TrialResults-center www.trialresultscenter.org

1 PD-L1 inhibitors

Trial	Treatments	Patients	Trials design and methods
atezolizumab vs chemotherapy			
IMvigor211 [NCT02302807] n=932 follow-up:	atezolizumab versus chemotherapy	patients with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen	Parallel groups open label
atezolizumab vs control			
IMvigor130 (monotherapy) <i>ongoing</i> [NCT02807636] n=NA follow-up:	Atezolizumab+Gemcitabine+Carboplatin/Cisplatin versus Placebo+Gemcitabine+Carboplatin/Cisplatin	Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma	open-design
IMvigor010 <i>ongoing</i> [NCT02450331] n=NA follow-up:	Atezolizumab versus Observation	Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy [IMvigor010]	Open Label
avelumab vs control			
JAVELIN Bladder 100 <i>ongoing</i> [NCT02603432] n=NA follow-up:	-	-	open-design
durvalumab vs control			
DANUBE <i>ongoing</i> [NCT02516241] n=NA follow-up:	-	-	open-design

References

IMvigor211, :
 IMvigor130 (monotherapy), :
 IMvigor010, :
 JAVELIN Bladder 100, :
 DANUBE, :

2 PD1 inhibitors

Trial	Treatments	Patients	Trials design and methods
pembrolizumab vs investigators choice of chemotherapy			
KEYNOTE-045 , 2017 [NCT02256436] n=542 follow-up:	pembrolizumab versus investigator's choice of chemotherapy with paclitaxel, docetaxel, or vinflunine	patients with advanced urothelial cancer that recurred or progressed after platinum-based chemotherapy	Parallel groups open-label
nivolumab vs placebo			
CheckMate 274 <i>ongoing</i> [NCT02632409] n=NA follow-up:	Nivolumab versus placebo	patients who have undergone radical surgery for invasive urothelial cancer	Parallel groups double-blind

References

KEYNOTE-045, 2017:

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017 Feb 17;: [28212060] 10.1056/NEJMoa1613683

CheckMate 274, :

Entry terms: nivolumab, MDX-1106, ONO-4538, BMS-936558, Opdivo

3 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.